Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis

Arthritis Research and Therapy

Volumn 12, Issue 3, 2010, Pages

  McCann, Fiona E ^a   Palfreeman, Andrew C ^a   Andrews, Melanie ^a,b   Perocheau, Dany P ^a   Inglis, Julia J ^a,c   Schafer, Peter ^d   Feldmann, Marc ^a   Williams, Richard O ^a   Brennan, Fionula M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREMILAST; COLLAGEN TYPE 2; DEXAMETHASONE; DRUG VEHICLE; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; DRUG DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; THALIDOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LETHARGY; LYMPH NODE; MALE; MOUSE; NONHUMAN; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; WEIGHT REDUCTION; ANIMAL; ARTHRITIS; BAGG ALBINO MOUSE; CELL CULTURE; DBA MOUSE; DISEASE MODEL; DRUG EFFECT; HOSPITALIZATION; METABOLISM; PATHOLOGY; SYNOVIUM;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; PHOSPHODIESTERASE 4 INHIBITORS; PHOSPHODIESTERASE INHIBITORS; ROLIPRAM; SEVERITY OF ILLNESS INDEX; SYNOVIAL MEMBRANE; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649804751     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3041     Document Type: Article

References (41)

1. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989, 2:244-247. 10.1016/S0140-6736(89)90430-3, 2569055.
2. Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003, 9:1245-1250. 10.1038/nm939, 14520364.
3. Sekut L, Yarnall D, Stimpson SA, Noel LS, Bateman-Fite R, Clark RL, Brackeen MF, Menius JA, Connolly KM. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol 1995, 100:126-132. 10.1111/j.1365-2249.1995.tb03613.x, 1534274, 7697910.
4. Semmler J, Wachtel H, Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells. Int J Immunopharmacol 1993, 15:409-413. 10.1016/0192-0561(93)90052-Z, 8505151.
5. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007, 76:481-511. 10.1146/annurev.biochem.76.060305.150444, 17376027.
6. Barber R, Baillie GS, Bergmann R, Shepherd MC, Sepper R, Houslay MD, Heeke GV. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol 2004, 287:L332-343. 10.1152/ajplung.00384.2003, 15047569.
7. Castro A, Jerez MJ, Gil C, Martinez A. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med Res Rev 2005, 25:229-244. 10.1002/med.20020, 15514991.
8. Beavo JA, Brunton LL. Cyclic nucleotide research -- still expanding after half a century. Nat Rev Mol Cell Biol 2002, 3:710-718. 10.1038/nrm911, 12209131.
9. Antoni FA. Molecular diversity of cyclic AMP signalling. Front Neuroendocrinol 2000, 21:103-132. 10.1006/frne.1999.0193, 10764527.
10. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005, 10:1503-1519. 10.1016/S1359-6446(05)03622-6, 16257373.
11. Boswell-Smith V, Spina D. PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast. Int J Chron Obstruct Pulmon Dis 2007, 2:121-129. 2695611, 18044684.
12. Schudt C, Tenor H, Hatzelmann A. PDE isoenzymes as targets for anti-asthma drugs. Eur Respir J 1995, 8:1179-1183. 10.1183/09031936.95.08071179, 7589403.
13. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001, 297:280-290.
14. Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008, 155:308-315. 10.1038/bjp.2008.307, 2567892, 18660825.
15. Giembycz MA. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol 2005, 5:238-244. 10.1016/j.coph.2005.04.001, 15907909.
16. Lehnart SE, Wehrens XH, Reiken S, Warrier S, Belevych AE, Harvey RD, Richter W, Jin SL, Conti M, Marks AR. Phosphodiesterase 4 D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 2005, 123:25-35. 10.1016/j.cell.2005.07.030, 2901878, 16213210.
17. Man HW, Schafer P, Wong LM, Patterson RT, Corral LG, Raymon H, Blease K, Leisten J, Shirley MA, Tang Y, Babusis DM, Chen R, Stirling D, Muller GW. Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem 2009, 52:1522-1524. 10.1021/jm900210d, 19256507.
18. Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, Bartlett JB, Loveland MA, Gilhar A, Cheung Y-F, Baillie GS, Houslay MD, Man H-W, Muller GW, Stirling DI. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a a model of psoriasis. British Journal of Pharmacology 2010, 159:842-855. 10.1111/j.1476-5381.2009.00559.x, 20050849.
19. Schett G, Wollenhaupt J, Papp K, Joos R, De Vlam KL, Rodrigues JF, Vessey A, Hu A, Zhu W, Sloan VS. Apremilast Is Active in the Treatment of Psoriatic Arthritis (PsA). ACR/ARHP 09 Scientific Meeting 2009, Philadelphia, Pennsylvania.
20. Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008, 24:1529-1538. 10.1185/030079908X301866, 18419879.
21. Molostvov G, Morris A, Rose P, Basu S, Muller G. The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures. Br J Haematol 2004, 124:366-375. 10.1046/j.1365-2141.2003.04777.x, 14717786.
22. Beech JT, Brennan FM. Preparation of mononuclear cells from synovial tissue. Methods Mol Med 2007, 135:105-119. full_text, 17951655.
23. Brennan FM, Chantry D, Jackson AM, Maini RN, Feldmann M. Cytokine production in culture by cells isolated from the synovial membrane. J Autoimmun 1989, (2 Suppl):177-186. 10.1016/0896-8411(89)90129-7, 2505790.
24. Kumar P, Delfino V, McShane P, Gray DW, Morris PJ. Rapid assessment of islet cell viability by MTT assay after cold storage in different solutions. Transplant Proc 1994, 26:814.
25. Terato K, Harper DS, Griffiths MM, Hasty DL, Ye XJ, Cremer MA, Seyer JM. Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity 1995, 22:137-147. 10.3109/08916939508995311, 8734568.
26. Williams RO. Collagen-induced arthritis in mice: a major role for tumor necrosis factor-alpha. Methods Mol Biol 2007, 361:265-284.
27. Van de Weerd HA, Bulthuis RJ, Bergman AF, Schlingmann F, Tolboom J, Van Loo PL, Remie R, Baumans V, Van Zutphen LF. Validation of a new system for the automatic registration of behaviour in mice and rats. Behav Processes 2001, 53:11-20. 10.1016/S0376-6357(00)00135-2, 11254988.
28. Inglis JJ, Notley CA, Essex D, Wilson AW, Feldmann M, Anand P, Williams R. Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. Arthritis Rheum 2007, 56:4015-4023. 10.1002/art.23063, 18050216.
29. Molnar-Kimber K, Yonno L, Heaslip R, Weichman B. Modulation of TNF alpha and IL-1 beta from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions 1993, (39 Spec No):C77-79. 10.1007/BF01972726, 8273592.
30. Prabhakar U, Lipshutz D, Bartus JO, Slivjak MJ, Smith EF, Lee JC, Esser KM. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int J Immunopharmacol 1994, 16:805-816. 10.1016/0192-0561(94)90054-X, 7843852.
31. Ross SE, Williams RO, Mason LJ, Mauri C, Marinova-Mutafchieva L, Malfait AM, Maini RN, Feldmann M. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol 1997, 159:6253-6259.
32. Souness JE, Foster M. Potential of phosphodiesterase type of IV inhibitors in the treatment of rheumatoid arthritis. IDrugs 1998, 1:541-553.
33. Laemont KD, Schaefer CJ, Juneau PL, Schrier DJ. Effects of the phosphodiesterase inhibitor rolipram on streptococcal cell wall-induced arthritis in rats. Int J Immunopharmacol 1999, 21:711-725. 10.1016/S0192-0561(99)00046-6, 10576617.
34. Francischi JN, Yokoro CM, Poole S, Tafuri WL, Cunha FQ, Teixeira MM. Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis. Eur J Pharmacol 2000, 399:243-249. 10.1016/S0014-2999(00)00330-7, 10884526.
35. Yamamoto S, Sugahara S, Ikeda K, Shimizu Y. Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059. Eur J Pharmacol 2007, 559:219-226. 10.1016/j.ejphar.2006.11.079, 17250824.
36. Marinova-Mutafchieva L, Williams RO, Funa K, Maini RN, Zvaifler NJ. Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum 2002, 46:507-513. 10.1002/art.10126, 11840454.
37. Seldon PM, Barnes PJ, Meja K, Giembycz MA. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol Pharmacol 1995, 48:747-757.
38. Zabel P, Wolter DT, Schonharting MM, Schade UF. Oxpentifylline in endotoxaemia. Lancet 1989, 2:1474-1477. 10.1016/S0140-6736(89)92929-2, 2574766.
39. Reimund JM, Raboisson P, Pinna G, Lugnier C, Bourguignon JJ, Muller CD. Anti-TNF-alpha properties of new 9-benzyladenine derivatives with selective phosphodiesterase-4- inhibiting properties. Biochem Biophys Res Commun 2001, 288:427-434. 10.1006/bbrc.2001.5786, 11606060.
40. Foey AD, Field S, Ahmed S, Jain A, Feldmann M, Brennan FM, Williams R. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis. Arthritis Res Ther 2003, 5:R317-328. 10.1186/ar999, 333423, 14680506.
41. Quinn LP, Stean TO, Chapman H, Brown M, Vidgeon-Hart M, Upton N, Billinton A, Virley DJ. Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration. J Neurosci Methods 2006, 156:218-227. 10.1016/j.jneumeth.2006.03.013, 16626808.